OncoMatch/Clinical Trials/NCT04848064
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Is NCT04848064 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Mogamulizumab and Natural Killer Cell Therapy for recurrent adult t-cell leukemia/lymphoma.
Treatment: Cyclophosphamide · Fludarabine · Mogamulizumab · Natural Killer Cell Therapy — This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, IIA, IIB, III, IIIA, IIIB, IV, IVA, IVB
stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy
Must have received: chemotherapy
Patients with adult T-cell leukemia/lymphoma (ATLL)...must have had at least one standard chemotherapy
Cannot have received: mogamulizumab
Exception: unless stopped previously for reasons other than progression or toxicity
Prior therapy with mogamulizumab unless stopped previously for reasons other than progression or toxicity.
Cannot have received: investigational therapy
Investigational therapies in the 2 weeks prior to beginning treatment on trial
Lab requirements
Blood counts
Absolute neutrophil count >= 1000/mm^3; Platelet count >= 50,000/mm^3
Kidney function
Calculated creatinine clearance >= 50 ml/min (by the Crockroft-Gault equation)
Liver function
Total bilirubin <= 2 x ULN; AST (SGOT) and ALT (SGPT) <= 3 x ULN (<= 5 x ULN with hepatic involvement by lymphoma)
Absolute neutrophil count >= 1000/mm^3; Platelet count >= 50,000/mm^3; Total bilirubin <= 2 x upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) <= 3 x ULN (<= 5 x ULN with hepatic involvement by lymphoma); Calculated creatinine clearance >= 50 ml/min (by the Crockroft-Gault equation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify